Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025July 31, 2025 at 09:00 AM EDT
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its second quarter 2025 financial results on Thursday, August 7, 2025. Amylyx’ senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates. To access the conference call, please dial +1 (800) 836-8184 (U.S. & Canada) or +1 (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations. The webcast will be archived and available for replay for 90 days following the event. About Amylyx Pharmaceuticals At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on three investigational therapies across several neurodegenerative and endocrine diseases in which we believe they can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20250731539063/en/ Contacts
Media
More NewsView MoreVia MarketBeat
Tickers
TTD
Strong Quarter, Weak Reaction: Why GitLab Shares Dropped ↗
Today 16:27 EST
Via MarketBeat
3 Signs Tesla Is Starting December on the Front Foot ↗
Today 15:16 EST
Via MarketBeat
Tickers
TSLA
Via MarketBeat
Recent QuotesView More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
|